Speaking by videoconference to the press in Brussels, the official noted that, despite the cases of the appearance of blood clots and the death of some people inoculated with this drug, “a causal relationship with the vaccine has not yet been proven”.
“But further analysis is possible and is still underway,” reinforced Emer Cooke.
It was for that reason that the EMA updated the information on the AstraZeneca vaccine on Tuesday, also indicating on that day that the drug is now called Vaxzevria, a commercial option that does not affect distribution to the European Union, he explained later. the pharmaceutical company to Lusa.
In this update on the drug, the European agency explained that, in addition to the name change, “a warning about very rare specific blood clot events has been included in the product information, while further investigations into a possible causal relationship with the disease are underway. vaccine”.
These episodes of blood clots and the death of people inoculated with this drug have led most European countries, including Portugal, to suspend the administration of this vaccine for a few days, a situation that was overcome after the EMA said it was “safe and effective. ”.
On Tuesday, the European regulator also said that since the vaccine was approved in the European Union (EU) on 29 January and until last Thursday, “more than 10 million doses of Vaxzevria have been administered in the EU and European Economic Area ”, well below the 120 million doses agreed between the pharmaceutical company and the European Commission for this first quarter.
Today, the EMA director said that a total of 62 cases of unusual blood clots (44 in the European Economic Zone) and 14 deaths had been reported to the European regulator and 14 deaths by March 22. This total, however, does not include all cases reported in Germany, he said.
With regard to the whole vaccination campaign in the EU, the European Commission announced at the end of last week that, until then, close to 62 million doses of vaccines had been administered in relation to the 88 million distributed.
Brussels attributed these low levels of inoculations to the problems with the delivery of vaccines from Vaxzevria (the new name of AstraZeneca’s drug) to the EU, demanding that the pharmaceutical company catches up with the delays in distribution and honors the contracted.
The European Commission revealed today that, by the end of this week, about 107 million doses of vaccines against covid-19 will reach the EU.
The Brussels target is that by the end of the summer, 70% of the adult population will be vaccinated.
Currently, four vaccines are approved in the EU: Pfizer / BioNTech (Comirnaty), Moderna, Vaxzevria and Janssen (Johnson & Johnson group, which will be distributed in April).
Get the latest news delivered to your inbox
Follow us on social media networks